Hepatitis B News and Research

Latest Hepatitis B News and Research

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Bristol-Myers Squibb awards $1 million grant to reduce hepatitis-related health disparities in Asia

The Bristol-Myers Squibb Foundation has awarded four new grants to help improve awareness, prevention and care of hepatitis B and hepatitis C in China and India.

25 Feb 2011

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

New research has determined that patients in the U.S. with hepatitis C virus are twice as likely to not have health insurance coverage compared with those without the disease.

24 Feb 2011

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

24 Feb 2011

New vaccine offers hope against Hepatitis C

Immunology: Three percent of the world's population is currently infected by hepatitis C. The virus hides in the liver and can cause cirrhosis and liver cancer, and it's the most frequent cause of liver transplants in Denmark.

24 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

FDA approves OraSure's rapid antibody test to detect HCV

OraSure Technologies, Inc. announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample.

22 Feb 2011

Johnson & Johnson completes cash tender for Crucell shares, declares offer unconditional

Johnson & Johnson and Crucell N.V. today announce that Johnson & Johnson has completed the tender offer for Crucell N.V. and has declared the offer unconditional.

22 Feb 2011

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.

22 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Viewpoints: Budget disappointment; supporting CLASS Act; health law's Medicaid 'mess'

If fiscal sanity is to be restored, Americans need to be told the hard facts — not just that the national debt is out of control and that deficits can't go on and on, but that getting the nation's finances in order will require going everywhere in the budget: domestic programs, defense spending and the big entitlement programs such as Social Security, Medicare and Medicaid that already consume three of every five dollars the government spends.

16 Feb 2011

NIH awards renewal grant to BMC's CARE unit to expand education of physicians-in-training

The Clinical Addiction Research and Education Unit in the Section of General Internal Medicine at BMC was recently awarded a $1,886,087 renewal grant from the National Institutes of Health to expand its education of physicians-in-training to become sophisticated implementers of substance use screening, assessment and treatment research.

14 Feb 2011

Chimerix announces completion of $45 million Series F financing

Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

14 Feb 2011

Janssen, Medivir collaborate to discover and develop drugs against dengue virus

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today that it has signed a collaboration agreement with Janssen Pharmaceutica N.V. for the discovery and development of drugs for the prophylaxis and treatment of dengue virus infection.

14 Feb 2011

HIV infection in mothers reduces disease resistance in babies: Study

New research suggests that babies whose mothers have HIV, but are not HIV-infected themselves, are born with lower levels of specific proteins in their blood called antibodies, which fight infection, compared with babies not exposed to HIV.

13 Feb 2011

53 share a needle & HIV risk due to a clinic blunder

Over 50 patients at a private radiology clinic were given blood tests using a needle device meant for single-patient use. Authorities have launched an investigation into the matter. These patients are all at risk of hepatitis B, hepatitis C and HIV infection. These cancer patients will need testing for the viruses, and again in three months. They had visited the hospital for a positron emission tomography (PET) scan for cancer detection.

13 Feb 2011

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Inhibitex, Inc. today reported that the U.S. Food and Drug Administration ("FDA") has designated the investigation of INX-08189, a potent guanosine nucleotide polymerase inhibitor for the treatment of chronic hepatitis C viral infection, as a Fast Track development program.

11 Feb 2011

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

A three-year, $3 million gift from the Richard J. Fasenmyer Foundation will fund research by a pair of Cleveland physicians into HIV and the body's response in autoimmune diseases.

11 Feb 2011

Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection.

10 Feb 2011

Hepatitis B News and Research

Latest Hepatitis B News and Research

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Bristol-Myers Squibb awards $1 million grant to reduce hepatitis-related health disparities in Asia

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

New vaccine offers hope against Hepatitis C

New nanoparticle can help develop vaccines against HIV, malaria

FDA approves OraSure's rapid antibody test to detect HCV

Johnson & Johnson completes cash tender for Crucell shares, declares offer unconditional

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Viewpoints: Budget disappointment; supporting CLASS Act; health law's Medicaid 'mess'

NIH awards renewal grant to BMC's CARE unit to expand education of physicians-in-training

Chimerix announces completion of $45 million Series F financing

Janssen, Medivir collaborate to discover and develop drugs against dengue virus

HIV infection in mothers reduces disease resistance in babies: Study

53 share a needle & HIV risk due to a clinic blunder

FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Hepatitis B News and Research

Latest Hepatitis B News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in